Latest Breaking News On - Merck press - Page 5 : comparemela.com

Merck: TEPMETKO (tepotinib) Receives Positive CHMP Opinion for Patients with Advanced NSCLC with METex14 Skipping Alterations

TEPMETKO is the first and only oral MET inhibitor to receive CHMP positive opinion in Europe for adult patients with advanced NSCLC harboring alterations leading to METex14 skipping Not intended

United statesMerck pressEuropean commissionDrug administrationGlobal head of development for the healthcareEuropean medicines agencyCommittee for medicinal products human useMedicinal productsHuman useDanny bar zoharGlobal headNew england journalLung cancerMerck press releases

Merck Expands Corporate Venture Fund M Ventures with a New Investment of € 600 Million

Merck Expands Corporate Venture Fund M Ventures with a New Investment of € 600 Million Darmstadt, Germany, December 8, 2021 – Merck, a leading science and technology company, today announced the expansion of its strategic, corporate venture capital arm M Ventures. The new investment of € 600 mil.

United statesNoord hollandArtios pharmaMerck expands corporate venture fundm venturesProgyny incMerck pressNew investmentExecutive boardIsraelm venturesMosa meatPadlock therapeuticsMerck press releases

Merck: New Data Presented at ECTRIMS Show Evobrutinib is First BTK Inhibitor to Demonstrate a Significant Reduction in Slowly Expanding Lesions (SEL) in Patients with RMS

Phase II post-hoc data show evobrutinib reduced acute and chronic inflammation processes in the central nervous system that may be early indicators of MS disease progression Additional data

United statesUnited kingdomComunidad autonoma de catalunaBrauti fritzenXavier montalbanHebron university hospitalMerck pressNeuroimmunology department neurorehabilitation unitSclerosis centre of catalonia cemcatGlobal head of development for the healthcareResearch in multiple sclerosisEuropean committee for treatmentEuropean committeeMultiple sclerosisMultiple sclerosis centreDanny bar zohar

Merck: New Real-World MAVENCLAD Data Show Sustained Effectiveness and Benefit on Quality-of-Life Measures in RMS Patients

New data presented at ECTRIMS 2021 highlight improvement in measures of physical and mental health of patients with relapsing multiple sclerosis (RMS) after one year of treatment with MAVENCLAD

United statesMerck pressEuropean commissionGlobal head of development for the healthcareEuropean unionResearch in multiple sclerosisEuropean committee for treatmentEuropean committeeMultiple sclerosisDanny bar zoharGlobal headCladribine tablets treatingOral cladribineOral cladribine addedPatients with active relapsing diseaseMerck press releases

Merck Completes Enrolment of Evobrutinib Phase III Clinical Trials Ahead of ECTRIMS 2021

Merck Completes Enrolment of Evobrutinib Phase III Clinical Trials Ahead of ECTRIMS 2021
q8dailynews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from q8dailynews.com Daily Mail and Mail on Sunday newspapers.

United statesSatakunta regionUnited kingdomComunidad autonoma de catalunaSanta cruzSouth koreaKymenlaakso regionCastillay leópEuropeb dicilloBarbara kornekMeritxell sabidAlessandra solariSophie peloquinPatrick vermerschRozemarijn mattiesingValeria ramaglia